Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Equity Average (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Equity Average for 10 consecutive years, with $709.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 22.61% to $709.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $709.9 million, a 22.61% decrease, with the full-year FY2025 number at $771.7 million, down 19.71% from a year prior.
  • Equity Average was $709.9 million for Q4 2025 at Intellia Therapeutics, down from $731.8 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $1.2 billion in Q1 2023 to a low of $520.3 million in Q2 2021.
  • A 5-year average of $907.5 million and a median of $942.1 million in 2024 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: surged 150.66% in 2021, then dropped 25.51% in 2025.
  • Intellia Therapeutics' Equity Average stood at $1.1 billion in 2021, then decreased by 4.04% to $1.0 billion in 2022, then rose by 1.31% to $1.0 billion in 2023, then fell by 12.12% to $917.3 million in 2024, then decreased by 22.61% to $709.9 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Equity Average are $709.9 million (Q4 2025), $731.8 million (Q3 2025), and $747.6 million (Q2 2025).